Dr. Ed Ramos is director of Digital Clinical Trials for the Scripps Research Digital Trials Center. Listen as we talk about empowering the individual with wearable health devices, the worst foods for spiking our blood sugar and the importance of lifelong flexibility.

Show notes:

PROGRESS study enrollment
https://progress.scripps.edu/ 

PROGRESS study explainer video
https://www.youtube.com/watch?v=UUdaMojHLuk&t=74s 

Ed’s bio
https://www.scripps.edu/science-and-medicine/translational-institute/about/people/ed-ramos/

Scripps Research Digital Trials Center
https://digitaltrials.scripps.edu/

Episode 25 - Ed Ramos: Reversing diabetes with personalized nutrition

Paul Biondi, Executive Partner, Flagship Pioneering and President, Pioneering Medicines

Paul joined Flagship Pioneering in 2019 as Executive Partner, Flagship Pioneering and President, Pioneering Medicines. In his role at Flagship, Paul works with growth company CEOs and their teams to achieve the best attainable value for each company and serves on the boards of selected Flagship companies including Seres Therapeutics, Valo Health. As a member of Flagship’s senior leadership team, Paul is involved in strategic and operational aspects of Flagship, including leading Pioneering Medicines.

Pioneering Medicines is an initiative of Flagship dedicated to conceiving and developing an innovative pipeline of life-changing treatments for patients. By harnessing the power of Flagship’s scientific platforms, Pioneering Medicines will create novel medicines that deliver benefits to more patients, sooner. Pioneering Medicines also enters into strategic partnerships to jointly conceive new products by combining partners' R&D priorities with Flagship's unique platform capabilities, providing partners access to the full spectrum of innovation across Flagship as well as the R&D expertise that Pioneering Medicines offers.

Paul joined Flagship Pioneering following a seventeen-year tenure at Bristol-Myers Squibb (BMS). Most recently, Paul served as the Senior Vice President of Strategy and Business Development where he had enterprise-wide responsibility for establishing and evolving BMS’s strategy, and for pursuing strategic transactions to access external innovation, enhance BMS’s capabilities and strengthen the company’s portfolio. Prior to this role, Paul held a series of leadership roles within BMS’ R&D organization overseeing strategy, portfolio and project management, and clinical and business operations.

Prior to BMS, Paul spent nine years at Mercer Management Consulting. He received his M.B.A. from the J.L. Kellogg School of Management at Northwestern University and his B.A. from Dartmouth College.

84. Leadership insights, Paul Biondi, President, Pioneering Medicines,Flagship Pioneering initiative

Synopsis: 

Kate Haviland is the CEO of Blueprint Medicines, a global precision therapy company that creates life-changing medicines for people with cancer and blood disorders. Applying an approach that is both precise and agile, they create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Kate discusses beginning her career at Genzyme before joining Blueprint Medicines, and what the transition to becoming CEO was like after having held various different roles at Blueprint. She also talks about how personalized medicine is transforming patient care, and the company’s focus on applying precision medicine to cancer and hematologic diseases. Finally, she dives into how the current environment informs how she approaches leading a publicly traded biotech and her perspective on partnerships.

Interested in learning more? Check out their recent approval here: https://rb.gy/4126e

Biography: 
Kate brings an impressive breadth of experience and leadership within the biopharmaceutical industry, as well as a substantial background in business development, commercial and strategic planning, and program management. Since April 2022, Kate has served as Chief Executive Officer of Blueprint Medicines. Kate joined Blueprint in 2016 as Chief Business Officer and later served as Chief Operating Officer, where she served as the founding chair of the portfolio management team, formed and executed business development strategy, drove global capital investment plans, and played a key role in capital market financings. In addition, she worked to drive the transformative growth of the company and support its evolution into a fully integrated business by developing and providing ongoing management of critical functions, including portfolio strategy, corporate development, commercial strategy, international, technical operations, corporate affairs, and information systems. Prior to joining Blueprint Medicines, Kate held leadership roles focused on building emerging, high-growth companies and advancing the development of innovative therapies in oncology and rare diseases as Vice President, Rare Diseases and Oncology Program Leadership at Idera Pharmaceuticals, Head of Commercial Development at Sarepta Therapeutics, Executive Director of Commercial Development at PTC Therapeutics, and roles in both corporate development and project management at Genzyme. She holds a B.A. from Wesleyan University with a double major in Biochemistry/Molecular Biology and Economics and an M.B.A. from Harvard Business School. Kate currently serves as chair of the board of directors at Fulcrum Therapeutics and is a member of the audit and compensation committees.

Pioneering precision therapies for cancer & blood disorders, Kate Haviland, CEO, Blueprint Medicines

Precision Medicine in Paediatric Cancer with Jonathan Bond, Owen Smith and Pamela Evans, episode 2 of Precisely: A Precision Medicine Podcast from Systems Biology Ireland at University College Dublin.

Three top Irish consultant haematologists discuss what makes precision medicine so relevant in childhood cancer research, diagnosis and treatment. Also, how parents and carers can work with their doctors to make informed decisions, and what challenges to expect in this area down the road.

Listen to the series on:
Apple: https://podcasts.apple.com/us/podcast/precision-medicine-in-paediatric-cancer-with-jonathan/id1706846108?i=1000629406937
Spotify: https://open.spotify.com/show/3uPqEVoXOTkVRlRyEEPRNO?si=1512496ec04441d8
Soundcloud: https://soundcloud.com/real-smart-media/sets/precisely-a-precision-medicine

Links:
Systems Biology Ireland (ucd.ie) https://www.ucd.ie/sbi/
Owen Smith | National Children's Research Centre (nationalchildrensresearchcentre.ie)https://www.nationalchildrensresearchcentre.ie/people/owen-smith/
Dr Pamela Evans | Children's Health Ireland (childrenshealthireland.ie) https://www.childrenshealthireland.ie/list-of-consultants/dr-pamela-evans/

Twitter: 
https://twitter.com/sysbioire
https://twitter.com/PrecisionOncIre 
https://twitter.com/jbond2019
https://twitter.com/Owensmith62Owen
https://twitter.com/CHIatCrumlin

Download

Precision Medicine in Paediatric Cancer with Jonathan Bond, Owen Smith and Pamela Evans

Welcome to AI Meets Life Sci, the newest video podcast from DeviceTalks and Drug Discovery & Development. Co-hosted by Kayleen Brown, managing editor at DeviceTalks, and Brian Buntz, pharma and biotech editor, the series offers a comprehensive look into the intersection of AI and life sciences from two unique perspectives.

WATCH the episode on Youtube - https://youtu.be/yW1fbtLoVg0
READ a TL;DR and deep-dive article - https://www.drugdiscoverytrends.com/can-ai-move-fast-and-cure-things-in-healthcare/

In the first segment, Paul Friedman, MD, Chair of the Department of Cardiovascular Medicine at Mayo Clinic, and Dave McMullin, Chief Business Officer of Anumana, discuss the groundbreaking collaboration between Mayo Clinic and Anumana in applying AI to enhance cardiovascular diagnostics, particularly through ECGs. They explore how AI can detect cardiac conditions early, with a focus on the EAGLE study's findings on AI-enhanced ECGs, and discuss Anumana's role in transforming these AI innovations into accessible medical devices.

In the second segment, Jeff Elton, PhD, CEO of ConcertAI, speaks to the transformative role of AI in clinical trials. He sheds light on AI's capabilities in improving patient selection for clinical trials and streamlining processes within life sciences. Dr. Elton emphasizes the broader implications of AI, from enhancing patient care to accelerating the development of new treatments, and discusses the ethical considerations of AI integration in healthcare.These interviews provide insights into the evolving roles of AI in various sectors like medtech, pharma, and biotech, showcasing its potential in transforming healthcare and research methodologies.

But that's not all! Join us for the next episode of AI Meets Life Sci, which features an interview with the Global Business Leader for Health and Life Sciences at Microsoft.

Catch the full episode on major podcast platforms and YouTube to dive deeper into the exciting convergence of AI and healthcare.

Thank you to our contributors, some of who include Catalyze Healthcare and SmartTRAK Business Intelligence, for providing vital support. To learn more about our contributors, visit: www.catalyzehealthcare.com and www.smarttrak.com.

Thank you for watching and listening to AI Meets Life Sci.

Mayo Clinic & Anumana transform ECG with AI; ConcertAI dishes on next-gen trials

Caris Precision Oncology Alliance Chairman, Dr. Chadi Nabhan, sits down for an engaging podcast interview with Dr. Ari VanderWalde, Global Head of Clinical Trials at Caris Life Sciences. Join them as they delve into the world of clinical trials, exploring the intricacies of clinical research, providing valuable insights into Caris' contributions, and the accessibility of these transformative opportunities.

For more information, please visit: www.CarisLifeSciences.com

Interview with Dr. Ari VanderWalde - Clinical Trials at Caris Life Sciences: The Path Forward

This episode of AI Meets Life Sci offers a comprehensive look at the ways AI is poised to upend the pharmaceutical industry. It features an in-depth keynote interview with Helen Merianos, Head of Sanofi's R&D Portfolio Strategy, who provides an inside look into Sanofi's commitment to go "all-in" on AI and data science. Merianos discusses the use of Sanofi's proprietary plai app – an AI-enabled smartphone app that draws from over a billion data points – and its role in establishing a data-driven culture across the company.

Additionally, the episode features Michelle Longmire, MD, Co-Founder and CEO of Medable, who discusses the use of generative AI in automating and accelerating clinical trial technology deployment timelines. These applications could cut some timelines in half. Longmire envisions AI's potential to drastically accelerate a development process. “Say there's 10,000 uncured or poorly suboptimally treated human diseases.” At the current pace of drug development, it might take about 200 years to create treatments for those conditions. “Imagine if we could 10x that,” Longmire says.

Join us for the next episode of AI Meets Life Sci, where we sit down with Ha Hong, PhD, Chief Artificial Intelligence Officer, Endoscopy at Medtronic.

Thank you to our sponsors Catalyze Healthcare and SmartTRAK Business Intelligence, for providing invaluable support.
catalyzehealthcare.com
smarttrak.com

Tune in and subscribe to AI Meets Life Sci on all major podcast channels and follow youtube.com/@DeviceTalks or AI Meets Life Sci YouTube Podcast to ensure you never miss an episode.

WATCH, LISTEN, and READ: https://www.drugdiscoverytrends.com/when-will-drug-development-have-its-chatgpt-moment-inside-ambitious-ai-initiatives-at-sanofi-and-medable/

Thank you for supporting AI Meets Life Sci!

Sanofi races to the AI forefront in Big Pharma; Plus, Medable's big promises for clinical trials

This episode of AI Meets Life Sci offers a comprehensive look at the ways AI is poised to upend the pharmaceutical industry. It features an in-depth keynote interview with Helen Merianos, Head of Sanofi's R&D Portfolio Strategy, who provides an inside look into Sanofi's commitment to go "all-in" on AI and data science. Merianos discusses the use of Sanofi's proprietary plai app – an AI-enabled smartphone app that draws from over a billion data points – and its role in establishing a data-driven culture across the company.

Additionally, the episode features Michelle Longmire, MD, Co-Founder and CEO of Medable, who discusses the use of generative AI in automating and accelerating clinical trial technology deployment timelines. These applications could cut some timelines in half. Longmire envisions AI's potential to drastically accelerate a development process. “Say there's 10,000 uncured or poorly suboptimally treated human diseases.” At the current pace of drug development, it might take about 200 years to create treatments for those conditions. “Imagine if we could 10x that,” Longmire says.

Join us for the next episode of AI Meets Life Sci, where we sit down with Ha Hong, PhD, Chief Artificial Intelligence Officer, Endoscopy at Medtronic.

Thank you to our sponsors Catalyze Healthcare and SmartTRAK Business Intelligence, for providing invaluable support.
catalyzehealthcare.com
smarttrak.com

Tune in and subscribe to AI Meets Life Sci on all major podcast channels and follow youtube.com/@DeviceTalks or AI Meets Life Sci YouTube Podcast to ensure you never miss an episode.

WATCH, LISTEN, and READ. Thank you for supporting AI Meets Life Sci!

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Andreas Obermair from the University of Queensland to discuss adverse events of open vs. minimally invasice radical hysterectomy. Andreas Obermair is a gynaecological oncologist in Brisbane, Australia promoting surgery with proven better patient outcomes.

LACC Trial: Adverse Events of Open vs Minimally Invasive Radical Hysterectomy with Andreas Obermaier

Victor Hanson-Smith is the Head of Computational Biology at Verge Genomics and is one of the world's leaders in mathematical modeling of eukaryotic genome evolution and function. He has co-authored 13 publications in peer-reviewed journals such as Nature and Science, and his work has been featured in the NYTimes and The Washington Post. He received his Ph.D. in Computer Science from the University of Oregon, and completed an NIH post-doctoral research fellowship in Evolutionary Genomics at UCSF. Additionally, he is a full-stack software engineer with 17 years experience building web applications, supercomputing simulations, and genomics pipelines.

31. Drug discovery for neurodegenerative diseases, Victor Hanson-Smith, Comp. Bio., Verge Genomics

AI Meets Life Sci explores the transformative role of AI and ML in the life sciences. The series zeroes in on major obstacles and opportunities in healthcare, presenting insights from Big Pharma, medtech OEMs, and Tech Giants, shaping the healthcare landscape and leading to better health outcomes. 

#medtech #pharma #technology #artificialintelligence #ai #machinelearning #videopodcast #podcast #medicaltechnology #pharmaceutical 

This video podcast is powered by DeviceTalks and is a collaboration between DeviceTalks and Drug Discovery & Development. Co-Hosts: Kayleen Brown, Managing Editor, DeviceTalks and Brian Buntz, Pharma Editor, Drug Discovery & Development. 

www.devicetalks.com/AI

This award-winning podcast brings Scripps Research discoveries to life, exploring the personal stories of the people behind the science on their quest to solve humanity’s biggest biomedical problems. 

Follow us on social media for more updates:
@scrippsresearch on Twitter and Instagram
@ScrippsResearchInstitute on Facebook
Scripps Research on LinkedIn

Real Smart Media is a Dublin based audiovisual production and web management company. Recording and podcasting events is a specialty.

The DeviceTalks Podcast Network delivers news, insights and commentary from Medtech industry leaders. Our podcasts will inspire medtech professionals to create better medtech devices and companies.

Explore the DeviceTalks Podcast Network, home to more than 8 podcasts:

• AbbottTalks
• AI Meets Life Sci
• Boston Scientific Talks
• DeviceTalks Weekly
• IntuitiveTalks
• MedtechWOMEN Talks
• MedtronicTalks
• Ortho Innovation Talks: Zimmer Biomet
• StrykerTalks

Biotech2050 Podcast is a think tank chronicling the disruptions changing the biotech industry over the next 50 years.

Popular tracks tagged #clinicaltrials